You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR MASOPROCOL

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for masoprocol

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00313534 ↗	Nordihydroguaiaretic Acid in Treating Patients With Nonmetastatic Relapsed Prostate Cancer	Terminated	National Cancer Institute (NCI)	Phase 1	2005-06-01	RATIONALE: Nordihydroguaiaretic acid may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of nordihydroguaiaretic acid in treating patients with nonmetastatic relapsed prostate cancer.
NCT00313534 ↗	Nordihydroguaiaretic Acid in Treating Patients With Nonmetastatic Relapsed Prostate Cancer	Terminated	University of California, San Francisco	Phase 1	2005-06-01	RATIONALE: Nordihydroguaiaretic acid may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of nordihydroguaiaretic acid in treating patients with nonmetastatic relapsed prostate cancer.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for masoprocol

Condition Name

Chart
Table

Condition Name for masoprocol
Intervention	Trials
Prostate Cancer	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for masoprocol
Intervention	Trials
Prostatic Neoplasms	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for masoprocol

Trials by Country

Map
Table

Trials by Country for masoprocol
Location	Trials
United States	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for masoprocol
Location	Trials
California	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for masoprocol

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for masoprocol
Clinical Trial Phase	Trials
Phase 1	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for masoprocol
Clinical Trial Phase	Trials
Terminated	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for masoprocol

Sponsor Name

Chart
Table

Sponsor Name for masoprocol
Sponsor	Trials
National Cancer Institute (NCI)	1
University of California, San Francisco	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for masoprocol
Sponsor	Trials
NIH	1
Other	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.